EpiBiome

About:

A precision microbiome engineering company developing alternatives to small-molecule antibiotics for use in agriculture and human health.

Website: http://www.epibiome.com

Twitter/X: EpiBiome

Top Investors: Viking Global Investors, Silicon Valley Bank, Matrix Capital Management, SV Tech Ventures, Alexandria

Description:

EpiBiome is a venture-backed precision microbiome engineering company tackling the challenge of antibiotic resistance by developing alternatives to small-molecule antibiotics for use in healthcare, veterinary and agriculture industries. Antibiotic-resistant bacteria surpass nuclear warfare, climate change, and terrorism as the biggest challenge facing humanity today. The pipeline of new antibiotics has slowed to a trickle, while the emergence of multi-drug resistant bacteria is on an unprecedented trajectory. These bacteria threaten to reverse more than 100 years of medical progress by making all but the most necessary surgical procedures too risky due to the threat of post-operative infection.

Total Funding Amount:

$7.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2013-11-01

Contact Email:

contact(AT)epibiome.com

Founders:

Aeron Tynes Hammack, Christina Tsai, Hsiao Lee, Nick Conley

Number of Employees:

11-50

Last Funding Date:

2017-03-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai